Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Exelixis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with metastatic or locally advanced or unresectable GIST who have intolerance of or disease progression following prior treatment with imatinib and/or sunitinib
ECOG (Eastern Cooperative Oncology Group) performance status ≤2
Must have measurable disease per RECIST (Response Evaluation Criteria in Solid Tumors)
Recovery from toxicity from prior therapy to Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 or to subject's baseline status
Adequate organ and marrow function
Sexually active subjects (male and female) must agree to use accepted methods of contraception during the course of the study and for 3 months following discontinuation of study drugs.
Female subjects of childbearing potential must have a negative pregnancy test at enrollment.
You may not be if
Therapy with imatinib or sunitinib within 14 days before the first dose of study drug
Chemotherapy, immunotherapy, targeted therapy, chemoembolization, or any investigational drug for the treatment of GIST after the last dose of imatinib or sunitinib
Anticoagulation with warfarin or coumarin-related compounds
Radiation to ≥25% of bone marrow within 28 days of study entry
Treatment with other investigational agents within 28 days of the first dose of XL820
Known central nervous systems metastases
Uncontrolled or intercurrent illness
Pregnancy or breast-feeding
Active bacterial or viral infection requiring systemic treatment
